Analyst Conference Summaries

Biotechnology Investor Aids


Tocagen Reports Brain Cancer Trial Failure for Toca FC

conference date: August 8, 2019 press release only

discloure: I owned this stock briefly. Sold on 9/12/2019 after the trial failed.

Q2 2019
  Aug 8, 2019    

Tocagen (TOCA) is a clinical-stage biotechnology company specializing in therapies for cancer.

Tocagen investor web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2019 William P. Meyers